Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment, compared to continued standard first-line systemic treatment in patients with unresectable oligometastatic CRC.
Primary Sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
50
Expected Date of Accrual
31 December 2026
Trial Chairperson
Dr Julie Chu, Peter MacCallum Cancer Centre, VIC, Australia
Trial Contact
qa@trog.com.au
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Related Post
10 December, 2025
Shaping the future: How TROG’s Emerging Investigators group is breaking down barriers for new researchers
SPECIAL INTEREST GROUP IN FOCUS: 10 December 2025 Dr
9 December, 2025
TROG’s inaugural Km’s for Cancer Research brings community together to support our work
LATEST NEWS: 9 December 2025 As we wrap up